Bangavax

Last updated

Bangavax
Vaccine description
Target SARS-CoV-2
Vaccine type mRNA
Clinical data
Other namesBancovid
Routes of
administration
Intramuscular
ATC code
  • None

Bangavax, also known as Bancovid, is a COVID-19 vaccine candidate developed by a Bangladeshi pharmaceutical company Globe Biotech Limited. [1] [2] [3] [4] [5] [6] The vaccine was initially called Bancovid. [7] On 23 November 2021, Globe Biotech has received ethical authorization from the Bangladesh Medical Research Council to conduct the first human trial. [8] [9]

History

On 2 July 2020, Globe Biotech Limited announced to be the first company from Bangladesh to have a COVID-19 vaccine under development. [1] The lone Bangladeshi company actually developed three COVID-19 vaccine candidates with different technologies. [10] The company named the mRNA based vaccine as Bancovid then renamed to Bangavax. [7] Globe Biotech took all the necessary steps from December 2020 to January 2021 to get the permission for ethical approval to conduct the first clinical trial of Bangavax. [4] However fate of the Bangavax is still uncertain due to an unknown reason.[ opinion ][ citation needed ] The Bangladesh government has been criticized for not approval the vaccine even after months to conduct the first clinical trial without any explanation. [11]

Globe Biotech published full research data in Vaccine journal in May 2021. [12]

After five months of delays Bangladesh Medical Research Council conditionally grants ethical permission. Before proceeding to human trials, they have to apply the vaccine on monkeys or chimpanzees before proceeding to human trials. According to Md Harunur Rashid, chairman of Globe Biotech, "There are two types of mRNA vaccines: pure and modified. The modified one requires trials on monkeys. As Globe is making the pure mRNA one, trials on monkeys are unnecessary. Furthermore, there are no third-party CROs in the country that could conduct monkey trials. Regardless of the drawbacks, Globe will fulfil all the conditions that the government requires it to." [13]

Related Research Articles

CureVac German bio-pharmaceutical company

CureVac N.V. is a German biopharmaceutical company that develops therapies based on messenger RNA (mRNA). Legally domiciled in the Netherlands and headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac had approximately 240 employees in November 2015 and 375 in May 2018.

Moderna American biotechnology company innovating on mRNA-based medicines

Moderna, Inc., is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to produce an immune response.

Novavax American biotechnology company

Novavax, Inc., is an American biotechnology company based in Gaithersburg, Maryland that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for Ebola, influenza, respiratory syncytial virus (RSV), and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its vaccine for COVID-19. Novavax has indicated it recognizes a continued need for innovative vaccines in other therapeutic areas and reports it has taken steps to ensure continued advancement of its influenza vaccine.

COVID-19 pandemic in Bangladesh Ongoing COVID-19 viral pandemic in Bangladesh

The COVID-19 pandemic in Bangladesh is part of the worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. The virus was confirmed to have spread to Bangladesh in March 2020. The first three known cases were reported on 8 March 2020 by the country's epidemiology institute, IEDCR. Since then, the pandemic has spread day by day over the whole nation and the number of affected people has been increasing. Bangladesh is the second most affected country in South Asia, after India.

Bharat Biotech Indian multinational biotechnology company and vaccine manufacturer

Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company headquartered in Hyderabad, engaged in the drug discovery, drug development, manufacture of vaccines, bio-therapeutics, pharmaceuticals and health care products.

BioNTech German biotechnology company

BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.

Covaxin Vaccine against COVID-19

Covaxin is an inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.

Novavax COVID-19 vaccine Vaccine candidate against COVID-19

The Novavax COVID-19 vaccine, codenamed NVX-CoV2373, or Nuvaxovid, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI), that is undergoing trials in India under the brand name Covovax. It requires two doses and is stable at 2 to 8 °C refrigerated temperatures.

Janssen COVID-19 vaccine Vaccine against COVID-19

The Janssen COVID-19 vaccine or Johnson & Johnson COVID-19 vaccine is a COVID-19 vaccine that was developed by Janssen Vaccines in Leiden, Netherlands, and its Belgian parent company Janssen Pharmaceuticals, subsidiary of American company Johnson & Johnson.

COVID-19 vaccination in India Immunisation programme against COVID-19 in India

India began administration of COVID-19 vaccines on 16 January 2021. As of 22 November 2021, India has administered over 1.17 billion doses overall, including first and second doses of the currently-approved vaccines. In India,80% of the eligible population received at least one shot, and number of fully vaccinated has surpassed those who have partially jabbed.

History of COVID-19 vaccine development Scientific work to develop a vaccine for COVID-19

COVID-19's caused virus, SARS-CoV-2, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

ZyCoV-D Vaccine candidate against COVID-19

ZyCoV-D is a DNA plasmid-based COVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council. It is approved for emergency use in India.

Inovio COVID-19 vaccine COVID-19 vaccine candidate

Inovio COVID-19 vaccine is a COVID-19 vaccine candidate developed by Inovio Pharmaceuticals.

ARCT-021 Vaccine candidate against COVID-19

ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.

PTX-COVID19-B Vaccine candidate against SARS-CoV-2 (COVID-19)

PTX-COVID19-B is a messenger RNA (mRNA)-based COVID-19 vaccine, a vaccine for the prevention of the COVID-19 disease caused by an infection of the SARS-CoV-2 coronavirus, created by Providence Therapeutics—a private Canadian drug company co-founded by Calgary, Alberta-based businessman Brad T. Sorenson and San Francisco-based Eric Marcusson in 2013. A team of eighteen working out of Sunnybrook Research Institute in Toronto, Ontario developed PTX-COVID19-B in less than four weeks, according to the Calgary Herald. Human trials with sixty volunteers began on January 26, 2021 in Toronto.

Walvax COVID-19 vaccine Vaccine candidate against COVID-19

ARCoV, also known as the Walvax COVID-19 vaccine, is an mRNA COVID-19 vaccine candidate developed by Walvax Biotechnology, Suzhou Abogen Biosciences, and the PLA Academy of Military Science. It is approved for Phase III trials in China, Mexico, Indonesia, and Nepal.

HGC019 Vaccine candidate against COVID-19

HGC019 is a mRNA based COVID-19 vaccine candidate being developed by Gennova Biopharmaceuticals and HDT Biotech Corporation with active support from Department of Biotechnology, India.

COVID-19 vaccination in Bangladesh

Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.

ARCT-154 Vaccine candidate against COVID-19

ARCT-154, also known as VBC-COV19-154 in Vietnam, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics. For its development, Arcturus collaborated with Vinbiocare, a Vietnamese company, for support with clinical trials and manufacturing.

COVID-19 vaccine clinical research

COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness and safety. 24 vaccines are authorized for use by national governments, including six approved for emergency or full use by at least one WHO-recognised stringent regulatory authority; while five are in Phase IV. 204 vaccines are undergoing clinical trials that have yet to be authorized. Nine clinical trials consider heterologous vaccination courses.

References

  1. 1 2 "Globe Biotech's Covid-19 vaccine 'BANCOVID' listed by WHO". Daily Sun. 17 October 2020. Archived from the original on 30 April 2021. Retrieved 28 April 2021.
  2. "'Bangavax' to get approval within a week". The Daily Observer. 25 April 2021. Retrieved 28 April 2021.
  3. "Globe Biotech applies for clinical trial". Prothom Alo. 17 January 2021. Retrieved 28 April 2021.
  4. 1 2 "Globe Biotech yet to get BMRC nod for human trials". Dhaka Tribune. 22 February 2021. Archived from the original on 29 April 2021. Retrieved 28 April 2021.
  5. Sumon S (8 January 2021). "Bangladesh joins global COVID-19 vaccine race with Bongavax set for clinical trial". Arab News. Archived from the original on 9 January 2021. Retrieved 28 April 2021.
  6. Baray JC, Khan MM, Mahmud A, Islam MJ, Myti S, Ali MR, et al. (January 2020). "BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response". bioRxiv. doi:10.1101/2020.09.29.319061. S2CID   222127616.
  7. 1 2 "Globe Biotech to produce vaccine candidate for clinical trial". The Financial Express. Dhaka. 6 January 2021. Retrieved 28 April 2021.
  8. "Bangavax gets BMRC approval to start human trials". Dhaka Tribune. 23 November 2021. Retrieved 23 November 2021.
  9. Report, Star Digital (23 November 2021). "Bangavax gets ethical permission for human trial". The Daily Star. Retrieved 23 November 2021.
  10. "3 Covid-19 vaccine candidates by Bangladesh's Globe Biotech enlisted in WHO draft landscape". The Daily Star. 17 October 2020. Archived from the original on 24 January 2021. Retrieved 4 May 2021.
  11. Masum O (6 May 2021). "Bangavax first buzzed with hope, then fizzled". bdnews24.com. Archived from the original on 9 May 2021. Retrieved 6 May 2021.
  12. Nag K, Baray JC, Khan MR, Mahmud A, Islam J, Myti S, et al. (18 May 2021). "An mRNA-based vaccine candidate against SARS-CoV-2 elicits stable immuno-response with single dose". Vaccine X . 39 (23): 3745–3755. doi: 10.1016/j.vaccine.2021.05.035 . PMC   8130517 . PMID   34039497.
  13. "Bangavax Covid vaccin: BMRC gives fresh conditions to Globe Biotech for human trials". Dhaka Tribune. 16 June 2021. Archived from the original on 28 June 2021. Retrieved 16 June 2021.